Antidepressant-like drugs are being developed by the pharmaceutical industry in a bid to tackle an epidemic of mental illness, according to a report by The Guardian.
The report, entitled Antidepressances: The Drug Industry’s answer.
Read moreAntidepressants are becoming more common and widely used in the world, with an estimated 1.3 million prescriptions written in 2016.
The vast majority of these prescriptions are for the selective serotonin reuptake inhibitors (SSRIs), which are antidepressants which aim to treat depression by lowering the levels of serotonin in the brain.
But the use of SSRIs has risen rapidly in recent years, with more than 300,000 people being prescribed the drugs last year, according the NHS.
The Guardian spoke to drugmakers to find out more about their work, how it affects people and what they’re working on.
The drug industry is a relatively new field in the pharmaceutical business.
In 2012, it was only possible to grow the drugs in a lab and develop them into pharmaceutical products.
It is still a relatively young industry, but according to The Guardian, the drugs are proving to be highly effective.
A spokesperson for the company AstraZeneca said: “As a leading global drug company, we have developed a wide range of antidepressants to address a wide variety of human health issues.
Our aim is to use them as a first line of defence against the complex and often-intrusive nature of the illness.”
In the UK, we provide an extensive range of medications to address conditions such as anxiety, depression, substance abuse and psychosis.
We have developed medications that are specifically tailored to specific patients.
“The UK is one of the top markets for antidepressants in Europe, accounting for roughly 40 per cent of the overall market.
The drugs are currently prescribed in England, Wales and Northern Ireland.
The UK has a relatively small population, so the number of prescriptions for antidepressants has been relatively low in recent decades.
According to the Royal College of Psychiatrists, there are currently approximately 8,000 prescriptions for SSRI’s in the UK.
This means that the drug industry may have the most to gain from making these drugs available in the country.
However, it does come at a price.
Antidepressant prescriptions are not regulated by the NHS and the drugs can cause severe side effects.
According to the Guardian, doctors have reported a number of serious side effects from the drugs.
In the United States, there have been reports of people being sent home from hospitals for days because they had taken too much of the medication.
In the US, the SSRIA is being used to treat a number and potentially hundreds of patients a year.
The National Alliance on Mental Illness, which represents the doctors who prescribe these drugs, said:”We don’t have the ability to monitor this, to prevent it, to know how it’s affecting people, because we can’t even tell people about the drugs we prescribe.”
We can’t give them any information about the risks of the drugs they’re taking and about their side effects.”
Antidepressans also have a long history of side effects in the US.
The drug has also been linked to heart attacks, strokes and cancer, with a study in the British Medical Journal claiming it may increase the risk of heart attacks.
Antihistamines are a newer class of drugs and were introduced in the late 1990s.
They are designed to help with anxiety, but the FDA is not aware of any cases of death linked to them.
The industry has also struggled with prescription rates in the United Kingdom.
According the Guardian:”As well as making drugs available to more patients, the NHS is spending £6.5bn on antidepressant drugs each year.”
There’s a real need to know what the benefits are of prescribing these medications, how effective they are and what kind of side-effects they’re having.
“If we are to reduce the need for antidepressants and improve quality of life for people, we need to have more data on the effects of these drugs on people.”
The company that makes the SSRI, AstraZeneca, is a major player in the industry and is one among a number.
The company is the world’s largest maker of SSRI drugs.
According a spokesperson for Astra Zeneca: “We are developing new and novel antidepressants that address specific medical conditions.”
Our medicines are clinically proven and have been clinically tested to demonstrate the benefits of these medications in a range of clinical trials.
“AstraZeneca is committed to developing medicines for the treatment of specific diseases and conditions.”
Antihists are also available over the counter in some parts of the world.
However, there has been a significant increase in their use.
In 2018, the National Alliance for Mental Illnesses (NAMI) issued a report which claimed the SSRRIs had led to a 50 per cent increase in the number prescribed in the past three years.
It also noted that an estimated 3.3million people were